436 related articles for article (PubMed ID: 8859727)
1. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.
Rosenberg SA; White DE
J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):81-4. PubMed ID: 8859727
[TBL] [Abstract][Full Text] [Related]
2. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
[TBL] [Abstract][Full Text] [Related]
3. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial.
Arai S; Meagher R; Swearingen M; Myint H; Rich E; Martinson J; Klingemann H
Cytotherapy; 2008; 10(6):625-32. PubMed ID: 18836917
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
5. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.
Andersen MH; Gehl J; Reker S; Pedersen LØ; Becker JC; Geertsen P; thor Straten P
Semin Cancer Biol; 2003 Dec; 13(6):449-59. PubMed ID: 15001164
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
7. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma.
Belldegrun A; Shvarts O; Figlin RA
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S88-92. PubMed ID: 10685666
[TBL] [Abstract][Full Text] [Related]
8. Reactivity to tyrosinase: expression in cancer (melanoma) and autoimmunity (vitiligo).
Merimsky O; Shoenfeld Y; Baharav E; Zigelman R; Fishman P
Hum Antibodies Hybridomas; 1996; 7(4):151-6. PubMed ID: 9140726
[TBL] [Abstract][Full Text] [Related]
9. Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma.
Dudek AZ; Mescher MF; Okazaki I; Math VT; Luo X; Curtsinger JM; Miller JS
Am J Clin Oncol; 2008 Apr; 31(2):173-81. PubMed ID: 18391603
[TBL] [Abstract][Full Text] [Related]
10. Immunology and immunotherapy of human malignant melanoma.
Bystryn JC
Dermatol Clin; 1985 Apr; 3(2):327-34. PubMed ID: 2937585
[TBL] [Abstract][Full Text] [Related]
11. Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2.
Lissoni P; Bordin V; Vaghi M; Fumagalli L; Bordoni A; Mengo S; Bucovec R; Fumagalli E; Malugani F; Ardizzoia A; Giani L; Gardani GS; Tancini G
Anticancer Res; 2002; 22(2B):1061-4. PubMed ID: 12168901
[TBL] [Abstract][Full Text] [Related]
12. [Malignant melanoma, leukoderma and vitiligo].
Kraus L; Landthaler M
Z Hautkr; 1980 Feb; 55(4):218-31. PubMed ID: 6996365
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of IL-2 immunotherapy in metastatic renal cell carcinoma in relation to the psychic profile as evaluated using the Rorschach test.
Messina G; Lissoni P; Bartolacelli E; Fumagalli L; Brivio F; Colombo E; Gardani GS
Anticancer Res; 2007; 27(4C):2985-8. PubMed ID: 17695482
[TBL] [Abstract][Full Text] [Related]
14. Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23.
Mittelman A; Chen ZJ; Liu CC; Hirai S; Ferrone S
Cancer Res; 1994 Jan; 54(2):415-21. PubMed ID: 8275478
[TBL] [Abstract][Full Text] [Related]
15. The longitudinal relationship between the systemic inflammatory response, circulating T-lymphocytes, interleukin-6 and -10 in patients undergoing immunotherapy for metastatic renal cancer.
Ramsey S; Aitchison M; Graham J; McMillan DC
BJU Int; 2008 Jul; 102(1):125-9. PubMed ID: 18336617
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients.
Luiten RM; Kueter EW; Mooi W; Gallee MP; Rankin EM; Gerritsen WR; Clift SM; Nooijen WJ; Weder P; van de Kasteele WF; Sein J; van den Berk PC; Nieweg OE; Berns AM; Spits H; de Gast GC
J Clin Oncol; 2005 Dec; 23(35):8978-91. PubMed ID: 16260696
[TBL] [Abstract][Full Text] [Related]
17. Induction of tolerance in autoimmune diseases rather than cure of cancer by interleukin-2 therapy.
Dejaco C; Duftner C; Schirmer M
J Clin Oncol; 2006 Jul; 24(20):e34; author reply e35-6. PubMed ID: 16829643
[No Abstract] [Full Text] [Related]
18. Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma.
Royal RE; Steinberg SM; Krouse RS; Heywood G; White DE; Hwu P; Marincola FM; Parkinson DR; Schwartzentruber DJ; Topalian SL; Yang JC; Rosenberg SA
Cancer J Sci Am; 1996; 2(2):91-8. PubMed ID: 9166506
[TBL] [Abstract][Full Text] [Related]
19. Physiopathology of IL-12 in human solid neoplasms: blood levels of IL-12 in early or advanced cancer patients, and their variations with surgery and immunotherapy.
Lissoni P; Mengo S; Mandalà M; Mauri E; Brivio F; Rovelli F; Confalonieri G; Longarini R; Bonfante A; Folli D; Meregalli S; Barni S; Tancini G; Giani L
J Biol Regul Homeost Agents; 1998; 12(1-2):38-41. PubMed ID: 9677534
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place.
Wagner JR; Walther MM; Linehan WM; White DE; Rosenberg SA; Yang JC
J Urol; 1999 Jul; 162(1):43-5. PubMed ID: 10379736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
